SCHEMBL1993044

SCHEMBL1993044

CC(=O)NC1=NC2(CCOc3ccccc32)CCS1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 4/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RAB9A P51151 3/20 0.34
CASP1 P29466 1/20 0.34
LMNA P02545 1/20 0.34
BCHE P06276 1/20 0.34
POLB P06746 1/20 0.34
APEX1 P27695 1/20 0.34
RECQL P46063 1/20 0.34
BLM P54132 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPC1 O15118 2/20 0.34
MITF O75030 1/20 0.34
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
KLF5 Q13887 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7938145 0.82 GAA (0.40) CYP1A2RAB9ALMNANPC1SMN1; SMN2
SCHEMBL1996400 0.78 BACE1 (0.42) BACE1
SCHEMBL15157254 0.75 BACE1 (0.39) BACE1BACE2
SCHEMBL7940166 0.72 BACE1 (0.43) BACE1BACE2
SCHEMBL7934145 0.72 BACE1 (0.38) BACE1BACE2
SCHEMBL15157931 0.72 RAB9A (0.39) RAB9ALMNAL3MBTL1NPC1SMN1; SMN2
SCHEMBL15157934 0.72 RAB9A (0.39) RAB9ALMNAL3MBTL1NPC1SMN1; SMN2
SCHEMBL7943032 0.69 SIRT2 (0.38) RAB9ALMNANPC1SMN1; SMN2KMT2A
SCHEMBL7941101 0.66 BACE1 (0.46) BACE1BACE2
SCHEMBL10247874 0.64 SMN1; SMN2 (0.42) KIF11SMN1; SMN2KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2318416-B1 SPIROAMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2013-09-04 EP disclosed
US-8501733-B2 Spiroaminodihydrothiazine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-08-06 US disclosed
US-20110152253-A1 SPIROAMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD (JP) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152253-A1 SPIROAMINODIHYDROTHIAZINE DERIVATIVES BACE1, BACE2, APP KIF11 4304/4885CYP1A2 1847/4885CYP2C19 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.